21459-Head and Neck Cancer-NA-1551

Head and Neck Cancer

A Phase 1, First-In-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

  • Details

ClinicalTrials.gov ID: NCT03978689
Diagnosis Type: NA
USOR Number:

  • Address

444 NW Elks Drive
Corvallis, OR 97330
P: (541) 754-1256

Search by practice name, trial titles, indicators and specific disease types.